Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 7.68%161.380.0%$1898.51m
OCGNOcugen, Inc. 6.32%8.750.0%$1079.84m
BNTXBioNTech SE 6.63%192.770.0%$872.52m
AMGNAmgen, Inc. 0.43%251.381.3%$740.91m
NVAXNovavax, Inc. 8.84%131.6979.8%$572.50m
SNSSSunesis Pharmaceuticals, Inc. 0.26%7.680.7%$536.86m
GILDGilead Sciences, Inc. -0.55%68.531.0%$504.56m
REGNRegeneron Pharmaceuticals, Inc. -0.11%516.622.7%$432.65m
ALXNAlexion Pharmaceuticals, Inc. 0.09%173.492.0%$412.31m
VRTXVertex Pharmaceuticals, Inc. 1.28%217.091.9%$311.54m
ILMNIllumina, Inc. 2.03%381.033.5%$302.74m
BIIBBiogen, Inc. -0.53%280.211.7%$269.43m
VXRTVaxart, Inc. 4.92%6.610.0%$240.79m
CRSPCRISPR Therapeutics AG 5.58%106.640.6%$171.41m
BNGOBionano Genomics, Inc. 22.45%5.400.0%$162.77m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.